









市场行情
/
股票
/
nasdaq-ebs
/

Emergent BioSolutions Inc

EBS

12.430USD

-0.200-1.58%

收盘 12/26, 16:00（美东）报价延迟15分钟

655.06M总市值

8.75市盈率 TTM



Emergent BioSolutions Inc

12.430

-0.200-1.58%

概览公司财务分析

概览

公司

财务

分析

关于 Emergent BioSolutions Inc 公司

Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.

Emergent BioSolutions Inc简介



公司代码EBS

公司名称Emergent BioSolutions Inc

上市日期Nov 15, 2006

CEOPapa (Joseph C)

员工数量900

证券类型Ordinary Share

年结日Nov 15

公司地址300 Professional Dr

城市GAITHERSBURG

上市交易所NASDAQ OMX NASDAQ Basic NYSE

国家United States of America

邮编20879

电话12406313200

网址https://emergentbiosolutions.com/

公司代码EBS

上市日期Nov 15, 2006

CEOPapa (Joseph C)

Emergent BioSolutions Inc公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Joseph C. (Joe) Papa

President, Chief Executive Officer, Director

342.50K

+21.24%

Mr. Richard S. (Rich) Lindahl

Chief Financial Officer, Executive Vice President, Treasurer

196.50K

-2.48%

Dr. Zsolt Harsanyi, Ph.D.

Independent Chairman of the Board

103.49K

+49.80%

Dr. Simon C Lowry, M.D.

Chief Medical Officer, Head of Research and Development

91.98K

+211.99%

Ms. Coleen Glessner

Executive Vice President - Quality and Ethics and Compliance

90.86K

-25.20%

Mr. Ronald B. Richard

Independent Director

78.17K

-8.33%

Ms. Jessica Perl

Senior Vice President, General Counsel, Corporate Secretary

68.39K

+1061.66%

Mr. Marvin L. White

Independent Director

68.25K

+101.64%

Mr. Keith A. Katkin, CPA

Independent Director

66.14K

-10.60%

Mr. William Hartzel

Senior Vice President - Manufacturing and Bioservices

62.55K

-0.97%

名称

名称/职务

职务

持股

持股变动

Mr. Joseph C. (Joe) Papa

President, Chief Executive Officer, Director

342.50K

+21.24%

Mr. Richard S. (Rich) Lindahl

Chief Financial Officer, Executive Vice President, Treasurer

196.50K

-2.48%

Dr. Zsolt Harsanyi, Ph.D.

Independent Chairman of the Board

103.49K

+49.80%

Dr. Simon C Lowry, M.D.

Chief Medical Officer, Head of Research and Development

91.98K

+211.99%

Ms. Coleen Glessner

Executive Vice President - Quality and Ethics and Compliance

90.86K

-25.20%

Mr. Ronald B. Richard

Independent Director

78.17K

-8.33%

收入明细

单位: USD更新时间: 10月6日周一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

业务USD

名称

营收

占比

Commercial Product sales

67.50M

47.91%

MCM Product sales

58.40M

41.45%

Contracts and grants

15.00M

10.65%

地区USD

名称

营收

占比

Non-U.S Government

83.10M

58.98%

U.S.Government

57.80M

41.02%

业务

地区

业务USD

名称

营收

占比

Commercial Product sales

67.50M

47.91%

MCM Product sales

58.40M

41.45%

Contracts and grants

15.00M

10.65%

股东统计

更新时间: 11月17日周一

持股股东

股东类型

持股股东

占比

BlackRock Institutional Trust Company, N.A.

7.43%

The Vanguard Group, Inc.

6.74%

State Street Investment Management (US)

4.66%

American Century Investment Management, Inc.

4.54%

Dimensional Fund Advisors, L.P.

4.08%

其他

72.56%

持股股东

占比

BlackRock Institutional Trust Company, N.A.

7.43%

The Vanguard Group, Inc.

6.74%

State Street Investment Management (US)

4.66%

American Century Investment Management, Inc.

4.54%

Dimensional Fund Advisors, L.P.

4.08%

其他

72.56%

股东类型

持股股东

占比

Investment Advisor

34.85%

Investment Advisor/Hedge Fund

30.34%

Hedge Fund

7.25%

Individual Investor

2.97%

Research Firm

1.58%

Pension Fund

1.08%

Bank and Trust

0.83%

Sovereign Wealth Fund

0.18%

Family Office

0.07%

其他

20.85%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

378

39.86M

83.14%

+128.30K

2025Q3

417

39.73M

84.87%

+2.04M

2025Q2

439

37.58M

87.40%

+1.14M

2025Q1

454

36.44M

84.55%

-9.64M

2024Q4

461

35.04M

82.31%

+2.84M

2024Q3

467

32.21M

81.37%

+1.29M

2024Q2

485

30.86M

99.60%

-5.54M

2024Q1

494

36.44M

103.37%

-17.72M

2023Q4

512

41.89M

103.68%

-1.06M

2023Q3

563

42.52M

113.85%

-6.21M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

BlackRock Institutional Trust Company, N.A.

3.83M

7.18%

+2.25M

+141.83%

Jun 30, 2025

The Vanguard Group, Inc.

3.58M

6.72%

+370.21K

+11.52%

Jun 30, 2025

State Street Investment Management (US)

1.74M

3.26%

+30.01K

+1.75%

Jun 30, 2025

American Century Investment Management, Inc.

2.29M

4.3%

-5.46K

-0.24%

Jun 30, 2025

Dimensional Fund Advisors, L.P.

1.85M

3.47%

+252.40K

+15.81%

Jun 30, 2025

Palisade Capital Management, LLC

1.10M

2.06%

-41.83K

-3.66%

Jun 30, 2025

Charles Schwab Investment Management, Inc.

1.11M

2.07%

+521.91K

+89.48%

Jun 30, 2025

Geode Capital Management, L.L.C.

1.28M

2.4%

+666.71K

+108.89%

Jun 30, 2025

Acadian Asset Management LLC

974.59K

1.83%

+141.27K

+16.95%

Jun 30, 2025

Connor, Clark & Lunn Investment Management Ltd.

986.67K

1.85%

+55.05K

+5.91%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

AdvisorShares Insider Advantage ETF

0.97%

Royce Quant Small-Cap Quality Value ETF

0.41%

State Street SPDR S&P Biotech ETF

0.28%

Federated Hermes MDT Small Cap Core ETF

0.23%

Harbor Human Capital Factor US Small Cap ETF

0.19%

Direxion Daily S&P Biotech Bull 3X Shares

0.18%

Pacer US Small Cap Cash Cows ETF

0.16%

Invesco RAFI US 1500 Small-Mid ETF

0.15%

Avantis US Small Cap Value ETF

0.14%

iShares Micro-Cap ETF

0.13%

AdvisorShares Insider Advantage ETF

占比0.97%

Royce Quant Small-Cap Quality Value ETF

占比0.41%

State Street SPDR S&P Biotech ETF

占比0.28%

Federated Hermes MDT Small Cap Core ETF

占比0.23%

Harbor Human Capital Factor US Small Cap ETF

占比0.19%

Direxion Daily S&P Biotech Bull 3X Shares

占比0.18%

Pacer US Small Cap Cash Cows ETF

占比0.16%

Invesco RAFI US 1500 Small-Mid ETF

占比0.15%

Avantis US Small Cap Value ETF

占比0.14%

iShares Micro-Cap ETF

占比0.13%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Emergent BioSolutions Inc的前五大股东是谁？



Emergent BioSolutions Inc 的前五大股东如下：
BlackRock Institutional Trust Company, N.A.持有股份：3.83M，占总股份比例：7.18%。
The Vanguard Group, Inc.持有股份：3.58M，占总股份比例：6.72%。
State Street Investment Management (US)持有股份：1.74M，占总股份比例：3.26%。
American Century Investment Management, Inc.持有股份：2.29M，占总股份比例：4.30%。
Dimensional Fund Advisors, L.P.持有股份：1.85M，占总股份比例：3.47%。